Steroid-Refractory Chronic Graft-Versus-Host Disease Treated With Ruxolitinib: A Narrative Review of Symptom Burden and Return to Daily Life. JCCSR 2023, 4 (1), 31-36. https://doi.org/10.5281/zenodo.22227762.